Stenabolic raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Casomorphin (from casein found in milk of mammals, including cows and humans) Gluten exorphin (from gluten found in cereals wheat, rye, barley), including: Gliadorphin/gluteomorphin Soymorphin-5 (from soybean) Rubiscolin (from spinach)
TIMP-1 is produced by almost every cell in the body. it has higher affinity towards MMP-9 and pro-MMP-9, but it does not inhibit some of the membrane-type MMPs (like MMP-14, MMP-16, MMP-18, MMP-19, MT1-MMP, MT2-MMP, MT3-MMP, and MT5-MMP). TIMP-2 is always present in most tissues; cells produce it all the time and growth factors don’t change its levels much. TIMP-3 stays in the extracellular matrix and is found especially in the basal membranes of the eyes and kidneys. TIMP-4 is mostly made in the heart, ovaries, kidneys, pancreas, colon, testes, brain, and fat tissue. Synthetic inhibitors generally contain a chelating group that binds the catalytic zinc atom at the MMP active site tightly. Common chelating groups include hydroxamates, carboxylates, thiols, and phosphinyls. Hydroxymates are particularly potent inhibitors of MMPs and other zinc-dependent enzymes, due to their bidentate chelation of the zinc atom. Other substituents of these inhibitors are usually designed to interact with various binding pockets on the MMP of interest, making the inhibitor more or less specific for given MMPs.
They called an ambulance which took him to Cedars-Sinai Medical Center, where Barker received stitches for an injured forehead and was released; he also hurt his left knee. Barker slipped and hit his head at home on June 19, 2017. His maid drove him to the emergency room, where Barker was checked and released. His representative said it was not as serious as his earlier fall. In October and November 2018, Barker was rushed to the hospital for severe back pain. Barker suffered another fall in January 2019, but he was not hospitalized. Barker's last public interview was with People in August 2021, in which he discussed The Price Is Right's upcoming 50th season on air. As of 2022, Burnet stated that, other than some non-prescription supplements such as collagen and a meal replacement drink to replenish nutrients not found naturally in Barker's vegetarian diet, he took only one prescription medication for hypothyroidism. On August 26, 2023, Barker died at his home in Los Angeles at the age of 99 of natural causes related to following several years fighting with Alzheimer's disease, a condition that Burnet and Barker's publicity team had kept hidden from the public. Hypertension, hyperlipidemia and hypothyroidism were listed as secondary causes of death. Barker was interred alongside his wife at Forest Lawn Memorial Park – Hollywood Hills.
==== Generalized anxiety disorder ==== Pregabalin has anxiolytic effects similar to benzodiazepines with less risk of dependence. The effects of pregabalin appear within one week of use, and are similar in effectiveness to lorazepam, alprazolam, and bromazepam, but pregabalin has demonstrated superiority by producing more consistent therapeutic effects for psychosomatic anxiety symptoms. Long-term trials have shown continued effectiveness without the development of tolerance, and, in addition, unlike benzodiazepines, it has a beneficial effect on sleep and sleep architecture, characterized by the enhancement of slow-wave sleep. It produces less severe cognitive and psychomotor impairment compared to benzodiazepines. A 2019 review found that pregabalin reduces symptoms, and was generally well tolerated.
{\displaystyle R_{0}>1,I(0)>0\Rightarrow \lim _{t\to \infty }(S(t),I(t),R(t))={\textrm {EE}}=\left({\frac {\gamma +\mu }{\beta }},{\frac {\mu }{\beta }}\left(R_{0}-1\right),{\frac {\gamma }{\beta }}\left(R_{0}-1\right)\right).}
Sources: en.wikipedia.org
=== From conventional antibodies === Alternatively, single-domain antibodies can be made from common murine, rabbit or human IgG with four chains. The process is similar, comprising gene libraries from immunized or naïve donors and display techniques for identification of the most specific antigens. A problem with this approach is that the binding region of common IgG consists of two domains (VH and VL), which tend to dimerize or aggregate because of their lipophilicity. Monomerization is usually accomplished by replacing lipophilic by hydrophilic amino acids, but often results in a loss of affinity to the antigen. If affinity can be retained, the single-domain antibodies can likewise be produced in E. coli, S. cerevisiae or other organisms.
== External links == Clinical trial number (NCT05656027 for "Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (CLARITY)" at ClinicalTrials.gov Clinical trial number (NCT05728944 for "Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (CLARITY)" at ClinicalTrials.gov Clinical trial number (NCT05753189 for "Phase 3 Safety Study for the Treatment of Presbyopia Subjects" at ClinicalTrials.gov
Strontium-90 (90Sr) is a radioactive isotope of strontium produced by nuclear fission, with a half-life of 28.91 years. It undergoes β− decay into 90Y (yttrium-90) with a decay energy of 546 keV. 90Sr has applications in medicine and industry and is an isotope of concern in fallout from nuclear weapons, nuclear weapons testing, and nuclear accidents.
Russell Findlay, leader of the Scottish Conservatives, says he will not attend a forthcoming anti-far-right summit being chaired by First Minister of Scotland John Swinney, saying the event is "not required" and is being used to "deflect from the SNP's dismal record". 20 April – Yvette Cooper condemns the vandalism of statues in Parliament Square during a transgender rights protest. 22 April – The Department for Business and Trade announces that the proposed redundancies at British Steel will not continue. Kemi Badenoch calls for the ban of recording "non-crime hate incidents". Deborah Taylor is announced as the chair of the public inquiry into the 2023 Nottingham attacks. The Scottish Government says it has no plans to bring back the Gender Recognition Reform (Scotland) Bill following the Supreme Court ruling on what defines a woman. Russell George withdraws as a Conservative candidate for the 2026 Senedd election after being charged over the general election betting scandal. 23 April – Kemi Badenoch rejects claims of a rift with Conservative frontbencher Robert Jenrick over whether the party should form a coalition with Reform UK after Sky News obtained footage of him speaking about wanting to "unite" the "fight" against Labour at the next general election. 24 April – Campaign group Hope Not Hate says that Reform UK is fielding local election candidates who have "posted hate, pushed far-right conspiracies and praised extremists" despite statements by Nigel Farage about improving the party's vetting process.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.